P
Peter De Porre
Researcher at Janssen Pharmaceutica
Publications - 62
Citations - 3773
Peter De Porre is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Abiraterone acetate & Prostate cancer. The author has an hindex of 19, co-authored 55 publications receiving 2799 citations. Previous affiliations of Peter De Porre include Utrecht University.
Papers
More filters
Journal ArticleDOI
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi,Nam Phuong Tran,Luis Fein,Nobuaki Matsubara,Alfredo Rodríguez-Antolín,Boris Alekseev,Mustafa Ozguroglu,Dingwei Ye,Susan Feyerabend,Andrew Protheroe,Peter De Porre,Thian Kheoh,Youn C. Park,Mary B. Todd,Kim N. Chi +14 more
TL;DR: The addition of abiraterone acetate and prednisone to androgen‐deprivation therapy significantly increased overall survival and radiographic progression‐free survival in men with newly diagnosed, metastatic, castration‐sensitive prostate cancer.
Journal ArticleDOI
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan,Matthew R. Smith,Karim Fizazi,Fred Saad,Peter F.A. Mulders,Cora N. Sternberg,Kurt Miller,Christopher J. Logothetis,Neal D. Shore,Eric J. Small,Joan Carles,Thomas W. Flaig,Mary-Ellen Taplin,Celestia S. Higano,Paul de Souza,Johann S. de Bono,Thomas W. Griffin,Peter De Porre,Margaret K. Yu,Youn C. Park,Jinhui Li,Thian Kheoh,V. Naini,Arturo Molina,Dana E. Rathkopf +24 more
TL;DR: Treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant, and further support the favourable safety profile of abiraton acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Apalutamide and Overall Survival in Prostate Cancer.
Matthew R. Smith,Fred Saad,Simon Chowdhury,Stéphane Oudard,Boris Hadaschik,Julie N. Graff,David Olmos,Paul N. Mainwaring,Ji Youl Lee,Hiroji Uemura,Peter De Porre,Andressa Smith,Sabine Brookman-May,Sabine Brookman-May,Susan Li,Ke Zhang,Brendan Rooney,Angela Lopez-Gitlitz,Eric J. Small +18 more
TL;DR: Extension of OS with apalutamide compared with placebo conferred impactful benefit in patients with nmCRPC, and there was a 22% reduction in the hazard of death in the apalUTamide group despite 19% crossover and higher rates of subsequent therapy in the placebo group.
Journal ArticleDOI
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Kim N. Chi,Andrew Protheroe,Alfredo Rodríguez-Antolín,Gaetano Facchini,Henrik Suttman,Nobuaki Matsubara,Zhangqun Ye,Bhumsuk Keam,Ronaldo Damião,Tracy Li,Kelly McQuarrie,Bin Jia,Peter De Porre,Jason L. Martin,Mary B. Todd,Karim Fizazi +15 more
TL;DR: The co-primary endpoints of the LATITUDE trial, overall survival and radiographic progression-free survival, have been published, and the results from the first pre-planned interim analysis are presented.
Journal ArticleDOI
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
Arlene O. Siefker-Radtke,Andrea Necchi,Se Hoon Park,Jesús GarcÃa-Donas,Robert Huddart,Earle F. Burgess,Mark D. Fleming,Arash Rezazadeh,Begoña Mellado,Sergei Varlamov,Monika Joshi,Ignacio Duran,Scott T. Tagawa,Anne OHagan,Anjali Narayan Avadhani,Bob Zhong,Peter De Porre,Yohann Loriot +17 more
TL;DR: Efficacy and safety of ERDA in the global open-label phase 2 study BLC2001 (NCT02365597) are reported, suggesting a need for new treatment options in this population of pts with select FGFRalt.